| 刘 涛,林晓明,李浩然,杨翔峰,陈正鲁.多西他赛联合洛铂同步调强放疗对中晚期食管癌近远期疗效、肿瘤标志物和生存质量的影响[J].现代生物医学进展英文版,2024,(13):2573-2577. |
| 多西他赛联合洛铂同步调强放疗对中晚期食管癌近远期疗效、肿瘤标志物和生存质量的影响 |
| The Effects of Docetaxel Combined with Loplatin Synchronous Intensity Modulated Radiotherapy on the Short-term and Long-term Efficacy, Tumor Markers, and Quality of Life in Advanced Esophageal Cancer |
| Received:December 23, 2023 Revised:January 18, 2024 |
| DOI：10.13241/j.cnki.pmb.2024.13.033 |
| 中文关键词: 中晚期食管癌 多西他赛 洛铂 同步放化疗 近远期疗效 肿瘤标志物 生存质量 |
| 英文关键词: Middle-late stage esophageal cancer Docetaxel Lobaplatin Synchronous radiotherapy and chemotherapy Short - and long-term therapeutic effects Tumor markers Quality of Life |
| 基金项目:广东省医学科研基金项目(A2021347) |
|
| Hits: 171 |
| Download times: 117 |
| 中文摘要: |
| 摘要 目的：评价多西他赛（DTX）联合洛铂（LBP）同步调强放疗（IMRT）对中晚期食管癌（EC）近远期疗效、肿瘤标志物和生存质量的影响。方法：选入我院2018年1月~2022年6月收治的中晚期EC患者276例，根据治疗方法不同分为对照组（IMRT治疗）和观察组（DTX联合LBP同步IMRT治疗），各138例。比较两组的近期疗效、肿瘤标志物、生存质量和毒副反应；随访至2023年11月，记录两组患者生存状态并绘制Kaplan-Meier生存曲线。结果：观察组客观有效率、无进展生存期、总生存期和治疗后EORTC QLQ-C30评分分别为89.86%、10.100（95%CI：9.552~10.648）个月、14.300（95%CI：13.940~14.660）个月和（75.52±9.35）分，对照组分别为68.84%、7.800（95%CI：7.307~8.293）个月、12.500（95%CI：11.643~13.357）个月和（64.71±9.81）分，观察组显著高于对照组（P<0.05）。观察组治疗后血清癌胚抗原、糖类抗原19-9、细胞角蛋白19片段水平分别为（14.94±3.25）ng/mL、（14.36±3.74）U/mL和（9.29±1.34）ng/mL，对照组分别为（22.37±3.86）ng/mL、（14.36±3.74）U/mL和（9.29±1.34）ng/mL，观察组显著低于对照组（P<0.05）。观察组胃肠道反应发生严重程度显著高于对照组（P＜0.05）。结论：与单纯IMRT相比，DTX联合LBP同步IMRT治疗中晚期EC的近期疗效显著，可有效降低血清肿瘤标志物水平，延长生存期，改善生活质量，且毒副反应可耐受。 |
| 英文摘要: |
| ABSTRACT Objective: To evaluate the effects of docetaxel (DTX) combined with loplatin (LBP) synchronous intensity modulated radiotherapy (IMRT) on the short-term and long-term efficacy, tumor markers, and quality of life in advanced esophageal cancer (EC). Methods: 276 patients with advanced EC admitted to our hospital from January 2018 to June 2022 were selected and divided into a control group (IMRT treatment) and an observation group (DTX combined with LBP synchronous IMRT treatment) based on different treatment methods, with 138 cases in each group. Compare the recent efficacy, tumor markers, quality of life, and toxic side effects between two groups. Follow up until November 2023, record the survival status of two groups of patients and draw Kaplan-Meier survival curves. Results: The ORR, PFS, OS, and post treatment EORTC QLQ-C30 scores of the observation group were 89.86%, 10.100 (95%CI: 9.552~10.648) months, 14.300 (95%CI: 13.940~14.660) months, and (75.52±9.35) points, respectively, while those of the control group were 68.84%, 7.800 (95% CI: 7.307~8.293) months, 12.500 (95%CI: 11.643~13.357) months, and (64.71±9.81) points, respectively, the observation group was higher than the control group (P<0.05). After treatment, the serum levels of CEA, CA199, and CYFRA21-1 in the observation group were (14.94±3.25) ng/mL, (14.36±3.74) U/mL, and (9.29±1.34) ng/mL, respectively, while those in the control group were (22.37±3.86) ng/mL, (14.36±3.74) U/mL, (9.29±1.34) ng/mL, respectively, the observation group was lower than the control group (P<0.05). The severity of gastrointestinal reactions in the observation group was higher than that in the control group (P<0.05). Conclusion: Compared with IMRT alone, DTX combined with LBP synchronous IMRT has a short-term therapeutic effect in the treatment of advanced EC, which can effectively reduce serum tumor marker levels, prolong survival, improve quality of life, and tolerate toxic side effects. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
